How to Test for H. Pylori: Breath, Stool, and Endoscopy

H. pylori infection is diagnosed through a handful of well-validated tests, broadly split into those that require an endoscopy and those that don’t. For most people who haven’t already been scheduled for a scope, the two go-to options are a urea breath test and a stool antigen test, both of which detect active infection with high accuracy. But the choice of test depends on the clinical situation, and some common approaches, particularly blood antibody testing, are far less useful than many patients and even some clinicians assume.

When Doctors Recommend Testing

Not everyone with an upset stomach needs an H. pylori test. Guidelines from the American College of Gastroenterology spell out the situations where testing is clearly warranted: anyone with an active peptic ulcer or a history of one, anyone with low-grade gastric MALT lymphoma, and anyone who has had early gastric cancer removed endoscopically should be tested and treated if positive.¹

Testing also makes sense for younger adults with persistent indigestion who don’t have worrying symptoms like weight loss or trouble swallowing. In that scenario, a non-invasive test is the first step, avoiding an endoscopy altogether. If you’re starting long-term use of anti-inflammatory painkillers like ibuprofen or naproxen, testing before you begin is recommended, because clearing an existing H. pylori infection lowers your risk of developing a stomach ulcer on those drugs.²

Less obviously, H. pylori testing is recommended for people with unexplained iron deficiency anemia that persists after a proper workup, and for adults with idiopathic thrombocytopenic purpura, a blood-clotting disorder. The connection between a stomach bacterium and low platelet counts surprises most people, but eradication can sometimes improve platelet levels.³

One situation where testing is explicitly not required: typical acid reflux symptoms without a history of peptic ulcer disease. If you just have heartburn, there’s no strong reason to go looking for H. pylori. That said, if you happen to get tested and come back positive, treatment is still offered, though its effect on reflux symptoms is unpredictable.

The Urea Breath Test

The urea breath test is the most widely endorsed non-invasive method for detecting active H. pylori. The principle is straightforward. You swallow a small amount of urea labeled with a carbon isotope (usually carbon-13, which is non-radioactive). If H. pylori is living in your stomach, its urease enzyme breaks down the urea, releasing labeled carbon dioxide that you breathe out. A device measures the isotope in your breath, and the result comes back the same day, often within minutes.

A meta-analysis pooling data from 23 studies found that the breath test has a pooled sensitivity of about 96% and specificity of about 93%, meaning it catches nearly all true infections and rarely calls a negative person positive.⁴ A more recent study looking at optimized cut-off values reported even higher numbers when the breath test was compared against both histology and PCR, with sensitivity and specificity both pushing past 98%.⁵ The test combines simplicity, accuracy, and safety, making it a natural first choice when endoscopy isn’t needed.⁶

A carbon-14 version of the test also exists and performs comparably. Carbon-14 is mildly radioactive, but the dose is extremely small. It tends to be less expensive than the carbon-13 version. Both are valid options.

The Stool Antigen Test

The stool antigen test detects H. pylori proteins in a stool sample. It’s another strong option for non-invasive diagnosis, and its main practical advantage is that it doesn’t require any special equipment at the testing site. You simply provide a sample, and the lab runs an immunoassay on it.

Accuracy depends on whether the test uses monoclonal or polyclonal antibodies. Monoclonal versions outperform polyclonal ones, particularly after treatment. One study found that the monoclonal stool antigen test achieved a sensitivity of about 92% and specificity of about 98%, compared to roughly 87% sensitivity and 98% specificity for the polyclonal version.⁷ Another study comparing specific commercial assays found similar patterns, with the monoclonal test offering significantly better sensitivity and negative predictive value.⁸

Cost-effectiveness analyses have found the stool antigen test to be a strong performer. A decision-analysis model simulating 1,000 patients on each test found that the stool antigen test produced the highest number of true outcomes (968) compared to serology (903) and the urea breath test (961), while remaining cost-effective for primary care settings.⁹ An earlier economic analysis found the stool test was more accurate than serology at low-to-intermediate prevalence, though the breath test could become preferable depending on local pricing.¹⁰

Why Blood Tests Are Mostly a Bad Idea

Blood-based serology, which detects antibodies your immune system made against H. pylori, is probably the most commonly ordered test in practice. It is also the least useful for most clinical purposes. The problem is fundamental: antibodies can linger in your blood for years after the infection has been cleared. A positive result tells you that at some point your body encountered H. pylori, not that the bacterium is still there. Serology cannot distinguish active infection from past exposure, and guidelines recommend against using it for diagnosis or to confirm eradication, except in narrow circumstances where other non-invasive tests cannot be used.¹¹

Yet serology persists in clinical practice because it’s cheap and the blood draw is simple. If you’ve had a positive blood test and nothing else, it’s worth discussing with your doctor whether a breath test or stool test would give a clearer picture. In settings with low H. pylori prevalence, the positive predictive value of serology drops sharply, meaning a significant fraction of positive results are false alarms.

Tests That Require an Endoscopy

When an upper endoscopy is being performed for other reasons, such as investigating persistent symptoms, evaluating an ulcer, or screening for precancerous changes, the procedure opens up several biopsy-based testing options. These are more invasive but offer their own advantages, including the ability to look at the stomach tissue directly and sometimes to test which antibiotics the infection will respond to.

The Rapid Urease Test

The rapid urease test works on the same principle as the breath test but uses a tissue sample. A small biopsy is placed in a gel or solution containing urea and a pH indicator. If H. pylori’s urease enzyme is present, the urea breaks down, the pH shifts, and the indicator changes color. Results can come back in minutes.¹² Best results come from taking biopsies from both the antrum and the body of the stomach. False positives are rare when the test kit includes an antibacterial agent and results are read within 24 hours. A newer “sweeping” technique, where the endoscopist rubs the test strip directly across a wider area of stomach mucosa, has shown markedly improved sensitivity compared to conventional single-biopsy sampling, especially in patients who have already been treated.¹³

Histology

Examining biopsied tissue under a microscope is another standard approach, particularly because it also reveals the state of the stomach lining itself, including inflammation, atrophy, and precancerous changes. Standard staining can identify the bacterium, but combining a routine stain with a special stain like modified Giemsa improves specificity. At least two staining methods are generally recommended for reliable diagnosis.¹⁴ The trade-off is turnaround time and cost; histology takes days, not minutes.

Culture

Growing H. pylori from a biopsy in the lab is the gold standard in one specific sense: it’s the only method that lets clinicians test the bacteria’s susceptibility to individual antibiotics. This becomes critical when first-line treatment fails. A systematic review found that H. pylori strains were successfully grown from about 81% of infected patients’ biopsies.¹⁵ The success rate climbed to around 86% in patients who had already failed two or more rounds of treatment, likely because clinicians were more aggressive about obtaining quality samples by that stage. Culture is slow and technically demanding, so it’s not used for routine first-time diagnosis, but it’s invaluable when treatment keeps failing.

The Medication Washout You Cannot Skip

Proton pump inhibitors, the acid-suppressing drugs like omeprazole, lansoprazole, and pantoprazole, are a major source of false-negative results across almost every H. pylori test. PPIs don’t just lower acid; they directly suppress the growth and urease activity of H. pylori. In lab studies, omeprazole and lansoprazole inhibited urease activity in over 90% of H. pylori strains within 40 minutes.¹⁶ In one clinical study, a third of patients whose infection had not actually been cured tested negative on the breath test while taking lansoprazole.¹⁷ Another study found that among H. pylori-positive patients on PPIs, 43% developed false-negative breath tests within the first 10 days of PPI use.¹⁸

The practical takeaway: you should stop PPIs at least two weeks before a breath test, stool antigen test, or biopsy-based test. Antibiotics and bismuth-containing products (like Pepto-Bismol) should be stopped at least four weeks before testing. If your doctor orders an H. pylori test without asking about these medications, bring it up yourself. A test taken while you’re on a PPI is significantly more likely to miss a real infection.

Confirming Eradication After Treatment

After you finish an H. pylori treatment regimen, your doctor should verify the infection is actually gone. This is typically done with either the urea breath test or the stool antigen test. The standard recommendation is to wait at least four weeks after completing therapy before retesting.¹⁹ One study found that a breath test performed as early as two weeks after finishing antibiotics yielded results comparable to testing at four to six weeks, but the four-week window remains the more conservative and widely followed standard.²⁰ You also need to be off PPIs for two weeks before the confirmation test, which means your doctor may need to coordinate the timing of your acid-suppression therapy.

Post-treatment testing matters more than many patients realize. Treatment failure rates for H. pylori have been climbing with rising antibiotic resistance. Skipping confirmation means you might assume the infection is gone when it isn’t, leaving you at continued risk for ulcer recurrence or ongoing stomach inflammation.

When Tests Become Less Reliable

Several clinical scenarios push the accuracy of standard tests lower than the numbers quoted above. Being aware of these edge cases helps you advocate for the right approach.

Active bleeding from a peptic ulcer is one of the most well-documented problem scenarios. In patients with bleeding ulcers, the sensitivity of the rapid urease test dropped to 80% in one study, compared to 96% in a non-bleeding control group.²¹ The mechanism is partly chemical: the albumin in blood buffers the pH change that the rapid urease test relies on to produce a color shift, effectively masking the result.²² If you’re tested during an emergency endoscopy for a bleeding ulcer, a negative rapid urease test shouldn’t be considered definitive. Follow-up testing with a breath test or stool test after recovery is a reasonable step.

Atrophic gastritis and intestinal metaplasia, conditions where the stomach lining has undergone long-standing damage, also reduce test accuracy. The sensitivity of the rapid urease test and the accuracy of histology both decrease as atrophy and metaplasia progress.²³ This is partly because H. pylori itself may disappear from the stomach as the lining changes, even though it caused the damage in the first place. Lower diagnostic accuracy of H. pylori on histology has been specifically described in the setting of intestinal metaplasia.²⁴ In these patients, combining multiple test methods, or using molecular techniques like PCR, can help avoid a missed diagnosis.

False Positives From Other Bacteria

Both the breath test and the rapid urease test work by detecting urease activity, but H. pylori is not the only bacterium that produces urease. In patients with reduced stomach acid, whether from atrophic gastritis, previous surgery, or heavy PPI use, other urease-producing bacteria can colonize the stomach and trigger a positive result. One study found false-positive breath test results in about 4% of patients, traced to species like Proteus mirabilis, Klebsiella pneumoniae, and Staphylococcus aureus colonizing the oral cavity and stomach. All of those patients had atrophic gastritis.²⁵ Patients with low stomach acid are especially prone to this because the acid barrier that normally prevents other bacteria from thriving in the stomach is weakened.²⁶

A case report of a child with repeatedly positive breath tests after confirmed H. pylori eradication illustrates how persistent this problem can be. Gastric microflora analysis revealed oral bacteria with urease activity were living in the stomach, driving the false-positive results.²⁷ For patients who keep testing positive after eradication despite no other signs of infection, this is worth keeping in mind before starting another unnecessary round of antibiotics.

Testing in Children

Pediatric guidelines take a more conservative approach than adult ones. The joint recommendations from ESPGHAN and NASPGHAN specify that invasive diagnostic testing for H. pylori should only be performed in children when treatment will actually be offered if the result comes back positive.²⁸ The reasoning is that H. pylori infection is common in children worldwide but causes symptoms or complications in only a small fraction. Testing everyone creates anxiety and unnecessary treatment.

Updated 2023 guidelines have added nuance. Invasive testing with antimicrobial susceptibility analysis is now recommended for choosing the right eradication therapy, reflecting the reality of rising antibiotic resistance. Molecular methods like PCR are accepted for detecting both the infection and resistance markers from biopsy samples. Noninvasive tests can be used as a screening method in children with a first-degree relative who has had gastric cancer. Interestingly, the updated guidelines no longer recommend H. pylori testing when investigating chronic immune thrombocytopenic purpura in children, reversing earlier guidance.²⁹

Molecular Testing and Resistance Detection

PCR-based molecular tests represent a newer generation of diagnostics that can do something traditional tests cannot: identify the infection and test for antibiotic resistance at the same time, without needing to grow the bacteria in culture. This matters because clarithromycin, one of the backbone antibiotics for H. pylori treatment, has seen resistance rates climb in many regions. A treatment regimen based on clarithromycin is unlikely to work if the specific strain is resistant to it.

Real-time PCR assays have been validated for both biopsy and stool specimens. In one clinical evaluation, PCR showed 100% sensitivity in biopsies and 98% in stool specimens, with 98% specificity in both, while simultaneously detecting the genetic mutations associated with clarithromycin resistance.³⁰ Similar assays have been developed specifically for stool-based testing, aiming to make resistance profiling possible without an endoscopy at all.³¹

These tests are not yet routine in every clinic or lab, but they’re becoming more widely available. If you’ve failed a first round of H. pylori treatment, asking whether molecular susceptibility testing is an option could help your doctor choose a regimen more likely to succeed the second time around.

Experimental and Point-of-Care Tests

Researchers are working on even less invasive approaches. A urinary rapid test for H. pylori antibodies has been evaluated in primary care and showed promising results, with sensitivity reaching 100% when compared against biopsy-based testing and accuracy of about 95%.³² However, like blood-based serology, urinary antibody tests face the fundamental limitation of not distinguishing current from past infection.

Saliva-based detection is another area of active development. A recent study described biosensor platforms using monoclonal antibodies to detect H. pylori antigens directly in saliva, achieving 100% agreement with gold-standard diagnostics in a small sample of 21 patients.³³ These technologies are still in early stages of validation and far from widespread clinical use, but they point toward a future where H. pylori testing could be as simple as a rapid strep test or home COVID kit, especially in parts of the world where access to breath testing equipment or endoscopy is limited.